Sana Biotechnology, Inc. (SANA) intrinsic value & 10-year financials
Sana Biotechnology, Inc. (SANA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.27
- Market cap
- $574.8M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -175.7%
- Free cash flow (FY2025)
- -$144.8M
SANA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$244.2M | -$0.96 | -$144.8M | — | -140.0% |
| FY2024 | — | -$266.8M | -$1.16 | -$256.6M | — | -118.7% |
| FY2023 | — | -$283.3M | -$1.46 | -$273.6M | — | -85.4% |
| FY2022 | — | -$269.5M | -$1.43 | -$310.9M | — | -54.1% |
| FY2021 | — | -$355.9M | -$2.14 | -$280.9M | — | -715.7% |
| FY2020 | — | -$285.3M | -$1.69 | -$161.9M | — | 59.7% |
| FY2019 | — | -$130.8M | — | -$111.6M | — | — |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Sana Biotechnology, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Sana Biotechnology, Inc. has historically struggled to out-earn its cost of capital, averaging just -57.6% ROIC.
Sana Biotechnology, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Sana Biotechnology, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.